Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.

Stier C, Koschker AC, Kim M, Stier R, Chiappetta S, Stein J

Clinical nutrition ESPEN26 May 2022Cited by 11 (Europe PMC)

PMID35871930DOI10.1016/j.clnesp.2022.05.009PepBankPUB-35871930

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In patients with life-threatening severe obesity, a rescue regimen of liraglutide, a leucine-rich amino acid infusion and a hypocaloric diet produced rapid weight loss in all patients.
In plain wordsIn people with life-threatening severe obesity, a rescue regimen with liraglutide, amino acids and a low-calorie diet gave fast weight loss.
Peptide
Liraglutide
Outcome
DecreaseRapid weight loss
Study
n = 26
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Rapid weight loss was observed in all patients on the RWR therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated whether a rescue weight reduction therapy (RWR) consisting of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, a leucine-rich amino acid infusion and a hypocaloric diet, can accelerate readiness for emergency surgery in patients with acutely life-threatening severe obesity.
Summary · context
In this proof-of-concept study, prospective data from patients treated with RWR (intervention group 1, n = 26) were mathematically matched with retrospective biometric data of 26 patients with severe obesity (historic control group 2) who underwent standard 6-month bridging with IB.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3587193001
02HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In patients with life-threatening severe obesity, all achieved operability after a mean of 20.7 days on a rescue regimen of liraglutide, a leucine-rich amino acid infusion and a hypocaloric diet.
In plain wordsIn people with life-threatening severe obesity, all became fit for surgery after 20.7 days on a liraglutide, amino acid and diet regimen.
Peptide
Liraglutide
Outcome
Not applicableTime to operability
Study
n = 26
Outcome group
Body weight · Metabolic and weight
Measurements
Time to operability
20.7 days
RWR bridging
Source sentences
Summary
All achieved operability after a mean RWR bridging duration of 20.7 ± 6.9 days.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated whether a rescue weight reduction therapy (RWR) consisting of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, a leucine-rich amino acid infusion and a hypocaloric diet, can accelerate readiness for emergency surgery in patients with acutely life-threatening severe obesity.
Summary · context
In this proof-of-concept study, prospective data from patients treated with RWR (intervention group 1, n = 26) were mathematically matched with retrospective biometric data of 26 patients with severe obesity (historic control group 2) who underwent standard 6-month bridging with IB.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3587193002
03HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In patients with life-threatening severe obesity, mean weight loss with the rescue regimen (27.5 kg) was not significantly different from 20.9 kg with 6-month balloon bridging (P = 0.0629).
In plain wordsIn people with life-threatening severe obesity, weight loss with the rescue regimen was not clearly different from weight loss with a stomach balloon.
Peptide
Liraglutide
Outcome
No significant changeBody weight loss versus intragastric balloon bridging
Study
n = 26
Comparator
Intragastric balloon bridging (historic control)
Outcome group
Body weight · Metabolic and weight
Measurements
Mean body weight loss
27.5 kg
RWR
Mean body weight loss
20.9 kg
intragastric balloon
Source sentences
Summary
Mean body weight loss during RWR was 27.5 ± 14.1 kg, compared with 20.9 ± 10.5 kg in group 2 (P = 0.0629).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated whether a rescue weight reduction therapy (RWR) consisting of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, a leucine-rich amino acid infusion and a hypocaloric diet, can accelerate readiness for emergency surgery in patients with acutely life-threatening severe obesity.
Summary · context
In this proof-of-concept study, prospective data from patients treated with RWR (intervention group 1, n = 26) were mathematically matched with retrospective biometric data of 26 patients with severe obesity (historic control group 2) who underwent standard 6-month bridging with IB.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3587193003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02616003

Preoperative Condition in Giant Obese Patients

Sana Klinikum Offenbachn = 50Apr 2014 to Apr 2018

Morbid Obesity · Bariatric Surgery Candidate

Trial page ClinicalTrials.govUpdated 23 Mar 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.